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Objective: Pain and depression are prevalent and treatable symptoms among patients with cancer, yet they are
often undetected and undertreated. The Indiana Cancer Pain and Depression (INCPAD) trial demonstrated
that telecare management can improve pain and depression outcomes. This article investigates the
incremental cost effectiveness of the INCPAD intervention.
Methods: The INCPAD trial was conducted in 16 community-based urban and rural oncology practices in
Indiana. Of the 405 participants, 202 were randomized to the intervention group and 203 to the usual-care
group. Intervention costs were determined, and effectiveness outcomes were depression-free days and
quality-adjusted life years.
Results: The intervention groupwas associated with a yearly increase of 60.3 depression-free days (S.E.=15.4;
Pb0.01) and an increase of between 0.033 and 0.066 quality-adjusted life years compared to the usual care
group. Total cost of the intervention per patient was US$1189, which included physician, nurse care manager
and automated monitoring set-up and maintenance costs. Incremental cost per depression-free day was US
$19.72, which yields a range of US$18,018 to US$36,035 per quality-adjusted life year when converted to that
metric. When measured directly, the incremental cost per quality-adjusted life year ranged from US$10,826
based on the modiﬁed EQ-5D to US$73,286.92 based on the SF-12.
Conclusion: Centralized telecare management, coupled with automated symptommonitoring, appears to be a
cost effective intervention for managing pain and depression in cancer patients.
Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Pain and depression are two of the most prevalent and disabling
symptoms among patients with cancer yet frequently are undetected
and undertreated [1–6]. Telecare interventions have been shown to be
effective atmanagingpain anddepression amongprimary care patients,
across a variety of health care settings, from largehealth systems to rural
hospitals [7–9]. Extending telecare to management of pain and
depression in patients with cancer is an emerging area of clinical and
research interest spurred by a long-standing failure to adequately
manage disabling symptoms among cancer populations [1–3,10].
The Indiana Cancer Pain and Depression (INCPAD) trial evaluated
the effectiveness of centralized telecare management coupled with0313573.
rant R01 CA-115369 from the
lis, IN 46202. Tel.: +1 317 630
ke).
CC BY-NC-ND license.automated symptommonitoring for patients with cancer. The INCPAD
trial was conducted in 16 community-based geographically dispersed
urban and rural oncology practices in Indiana and showed that
telecare management improved both cancer-related pain and de-
pression over the 12 months of the trial [11].
In the present paper, we investigate the cost effectiveness of the
INCPAD telecare intervention. New contributions made by this paper
include mapping of information from outcome assessment question-
naires into depression-free days (DFDs) and quality-adjusted life
years (QALYs), accounting for intervention costs and a regression
analysis of the effectiveness measures to allow comparisons with
other pain and depression management interventions.
2. Methods
2.1. Experimental design and sample
The INCPAD trial design [12] and its effectiveness in reducing pain
anddepression [21]havebeenpreviouslydescribed. Patients presenting
for oncology clinic visitswere screened for depression andpain. Patients
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telephone eligibility interview to determine if they had clinically
signiﬁcant depression or pain. Depression had to be at least moderately
severe, deﬁned as a Patient Health Questionnaire nine-item depression
scale score ≥10 and endorsement of either depressed mood and/or
anhedonia. Pain had to be: (a) deﬁnitely or possibly cancer-related; (b) at
leastmoderately severe, deﬁned as a score of≥6 on the “worst pain in the
past week” item of the Brief Pain Inventory (BPI). Excluded were
individuals who did not speak English; had moderately severe cognitive
impairment, schizophreniaorotherpsychosis; hadapendingpain-related
disability claim;werepregnant; orwere inhospice care. Informedconsent
and Health Insurance Portability and Accountability Act authorization
were obtained from eligible patients who desired to participate.
Of the 405 eligible participants who consented to enroll in the
study, 202 patients were randomized to the intervention group and
203 to the usual-care group. Randomization was stratiﬁed by
symptom type: 131 patients had depression only, 96 had pain only
and 178 had both depression and pain. Patient mean age was 58.8
years, and 68% were women. The type of cancer was breast (29%),
lung (20%), gastrointestinal (17%), lymphoma or hematological (13%),
genitourinary (10%) and other (10%). The phase of cancer was newly-
diagnosed (37%), disease-free or maintenance therapy (42%) and
recurrent or progressive (20%).
2.2. Outcomes
Outcomes were assessed by blinded telephone interviews over 12
months (baseline and at Months 1, 3, 6 and 12, with some of the
outcomes assessed less frequently). Depression, pain, mental health
and disability outcomes were used to estimate the DFDs and QALYs
associated with the intervention.
DFDs during the 12-month follow-up period were calculated from
the HSCL-20 scores [13,14]. At each assessment, patients received a
portion of a DFD for that day according to the following algorithm: if
patients had anHSCL-20 score of 0.50 or less, theywere coded as having
oneDFD; if patients hadHSCL-20 score of 2.00 or greater, zeroDFDs; and
if patients scored between 0.50 and 2.00, they were assigned a DFD
value between zero and one by linear interpolation (e.g., a HSCL-20
score of 1.25 was coded as 0.5 DFD). DFDs between assessments
(intervals of baseline to Month 1, Month 1 to Month 3, etc.) were
calculated by averaging the DFDs between the two assessments and
multiplyingby thenumberof days between assessments. DFDs between
assessments were summed for all assessment intervals to yield the
number of DFDs during the 12 month follow-up.
DFDs were calculated two ways, depending on how the missing
follow-up assessments were coded. The ﬁrst measure excluded patients
who had missing follow-up assessments or died during the trial. The
second imputed DFDs by: (a) carrying the last observation forward to
impute themissing follow-up assessment and (b) including patientswho
died up to their last assessment prior to death. Patients who died before
their Month 1 assessment were excluded from imputation. DFDs
represent an estimate of the number of days out of the year a patient is
depression free by summarizing the HSCL-20 scores measured at each
follow-up period into a single measure. Twelve-month follow-up period
yields one measure of DFD for a given patient. Because DFD is
not repeatedly measured for a given patient but summative over the
12-months, last observation carried forward (LOCF) was considered
preferable to mixed models repeated measures (MMRM) analysis.
Moreover, LOCF and MMRM produced similar results for outcomes in
the INCPAD trial [11].
QALYs were calculated using four methods. First, QALYs were
derived from DFDs [13,15,16]. Previous literature estimated that
depression corresponds to a 0.2 to 0.4 decrement in quality-of-life
weights, so 1 year of depression would reduce QALYs by the same
decrement. The number of DFDs out of the year would correspond to a
proportional reduction in QALYs. For example, a reduction of 30 DFDs isequivalent to a 0.016 to 0.033 reduction in QALYs, depending on
whether 0.2 or 0.4 was used. Second, patient responses to the SF-12
were used to generate preference-based quality-of-life weights known
as the SF-6D [17]. Third, amodiﬁed EQ-5D surveywas constructed from
the responses to a combination of depression, pain, mental health and
disability items from various questionnaires and used to generate
quality-of-life weights [18] (Appendix 1). Fourth, a visual analog scale
on a 0–10 scale was used to measure quality of life during the past
month at each assessment. Several methods for calculating QALYs were
used because DFDs only applied to the subgroup of 309 depressed
patients and because the SF-6D and EQ-5D may produce divergent
results [19–25]. Thus, derivation of QALYs from several methods
provides a possible range of QALYs and in effect a type of sensitivity
analysis.Quality-of-lifeweights at eachassessmentwere rescaled to0 to
1, and QALYs were calculated by area under the time curves.
2.3. Costs
Costs were calculated from a payer's perspective. Intervention cost per
patient was determined using provider payroll data and capital expendi-
ture associated with the intervention. The nurse care manager time
devoted to each study patient was maintained in a detailed log, and
physician time spent inweekly caremanagement conferences and stafﬁng
outside of these weekly meetings was determined. Using annual salaries
including fringe rates of the physician supervisor and nurse care manager
combined with the hours they devoted to the study over the course
of the INCPAD trial allowed us to calculate physician and nurse costs.
Further details regarding cost determinations are provided in Appendix 2.
Capital expenditures for startup and maintenance of the automat-
ed symptom monitoring were included as an intervention cost.
Automated symptom monitoring costs can be spread over a number
of patients hence intervention cost per patient will decrease with
increasing number of patients. In addition, after paying these startup
costs, subsequent maintenance costs are fairly low. However, the cost
of purchasing the automated symptom monitoring may vary
depending on the purchasing power of the buyer.
Since INCPAD involved multiple community-based practices
across the state of Indiana, it was not possible to obtain prescription
or other medical cost data. However, neither patient-reported health
care use nor co-interventions differed signiﬁcantly between the
intervention and the usual care group [11].
2.4. Analysis
Incremental intervention costs and effectiveness were calculated
separately for (a) all 202 patients in the intervention group, including
those who had only pain, only depression or both pain and depression
and (b) the subset of 154 patients in the intervention group with
depression, including those with only depression and those with both
pain and depression. This is because the cost-effectiveness analyses
based upon the SF-12 and EQ-5D used the full sample of 405 patients
(202 intervention and 203 control), while the analysis based upon
DFDs used the 309 patients with depression (154 intervention and
155 control). Physician and nurse time cost was calculated based on
administrative data on annual salary plus fringe and hours spent on
the intervention during the year (Appendix 2).
The effect of the intervention on each outcomemeasure (DFDs, SF-
12 quality-of-life weights, visual analog scale and modiﬁed EQ-5D
quality-of-life weights) at each assessment timepoint (Month 1, 3, 6
and 12 for visual analog scale, DFDs and the modiﬁed EQ-5D; Months
3 and 12 for the SF-12) was estimated using ordinary least squares
(OLS) regression, controlling for baseline value of the outcome
measure and standard sociodemographic variables (age, gender,
education, race, marital status, employment and income). Because
patients were recruited from a large number (i.e., 14) of different
clinics which in turn contributed a wide range (9 to 78) of enrolled
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patients within clinics [26]. Each outcome at a given assessment
month was modeled separately in cross-sectional regressions.
Coefﬁcients of the intervention dummy variable were used to test
for signiﬁcance of the intervention effect. Since the intervention was
centralized and telephone-administered to patients throughout the
entire state of Indiana, we did not expect an unobserved hospital or
clinic-level effect in these randomized data. Accordingly, those
variables were omitted from the regression.
Based on the regression coefﬁcients, average outcomes (DFD, SF-
12 quality-of-life weights, modiﬁed EQ-5D quality-of-life weights) for
the intervention group and the intervention group were predicted
holding the covariates at observed values [15,27]. The area under the
curve that captured the predicted quality-of-life weights over time
was used to calculate QALYs. As mentioned earlier, the analysis for
DFD was done with and without imputation. Analyses for SF-12 and
EQ-5D were done only without imputation. Quality-of-life weights
derived from the visual analog scale were not signiﬁcantly different
between the intervention and usual care group, and therefore, no
further cost-effectiveness calculations were performed.
3. Results
3.1. Costs
Table 1 summarizes the costs attributable to the intervention. Total
physician time cost to treat all intervention patients was US$43,226,
and the resulting physician cost per patient was US$214. Total
physician time cost to treat the patients with depression was US
$43,226, and the resulting physician cost per patient was US$281.
Total nurse care manager time cost to treat all intervention
patients was US$71,224, and the resulting total nurse care manager
cost per patient was US$353. Total nurse care manager time cost to
treat the patients with depression was US$61,906, and the resulting
total nurse care manager cost per patient was US$402.
The cost of the automated monitoring system and its maintenance
during the trial was US$78,000. Spread out over all intervention
patients, monitoring cost per patient was US$386. Spread out over the
patients with depression, monitoring cost per patient was US$506.
The sum of the physician, nurse care manager and monitoring cost
was US$953 per patient for all intervention patients and US$1189 per
patient for the patients with depression.
Projected costs of the intervention for new patients enrolled after
the trial should decrease because the automated monitoring system is
already set up and only maintenance costs of the system would be
required. Post start up, automated monitoring maintenance cost was
estimated to be about US$20,000 over the 3 years of the trial, whichTable 1
Costs of INCPAD intervention for entire trial and 12-month per patient costs⁎
Intervention component
(202 out of 405 total sample)
Total trial
costs (US$)
Per patient 12-month
costs (US$)
Physician time 43,226 213.99
Nurse care manager time 71,224 352.59
Automated monitoring
start-up/maintenance
78,000 386.14
Total 192,450 952.72
Intervention component
(154 out of 309 depressed subgroup)
Total trial costs
(US$)
Per patient 12-month
costs (US$)
Physician time 43,226 280.69
Nurse care manager time 61,906 401.99
Automated monitoring
start-up/maintenance
78,000 506.49
Total 183,132 1189.17
⁎ For details regarding cost calculations, see Appendix 2. First column includes total
intervention costs for all patients during the 42 months of the trial. Second column is
the per patient cost for the 12 months each patient was in the trial.would reduce the incremental cost per new intervention patient
treated to about US$666 and cost per new depressed patient treated
to about US$813.
3.2. Effectiveness
OLS regression estimated the effect of the intervention on DFDs
controlling for baseline characteristics. Table 2 summarizes the incre-
mental cost-effectiveness ratios (ICERs). As previously noted, the
regression model for DFD only included the subset of patients who had
depression. From the subset of 309 depressed patients, 187 patients had
complete follow-up, with 90 in the intervention group and 97 in usual
care group. For these patients, predicted average DFD during the 12-
month follow-up for the intervention groupwas 227.38 days and, for the
usual care group, was 167.08 days. Thus, the intervention group was
associated with an increase of 60.30 DFDs (S.E.=15.38; Pb0.01)
compared to the usual-care group. Based on the existing estimates of
the increase in quality of life of from 0.2 to 0.4 per additional DFD, the
interventionwasassociatedwithgainof between0.033and0.066QALYs.
From the subset of 309 depressed patients, 298 patients had either
complete or imputed follow-up data on DFDs, with 148 in the
intervention group and 150 in usual care group. The intervention
group was associated with an increase of 44.12 DFDs (S.E.=12.86;
Pb0.01) compared to the usual care group. The predicted average DFD
during the 12-month follow-up for the intervention group was 185.81
days and for the usual care groupwas 141.70 days. Based on the existing
estimate of the increase in quality of life in DFDs, the intervention was
associated with gain of between 0.024 and 0.048 QALYs.
Quality-of-life weights from SF-12 and modiﬁed EQ-5D were also
modeled using OLS regression. The regression model for quality-of-life
weights included all patients. However, patients included in the
regression model decreased over time, due to death or nonresponse,
and those with missing data were not imputed. For the SF-12, 405
patients were included at baseline but diminished to 267 patients at
month 12. For EQ-5D, 362 patients were included at baseline but fell to
211 patients at month 12.
The effect of the intervention on SF-12-based quality-of-life weight
was not signiﬁcant at Month 3 but signiﬁcant at month 12 with
intervention group associated with 0.03 point (S.E.=0.02; Pb0.05)
higher quality-of-life weight. The gain in SF-12 quality of life based on
the area under the weight curve over 12 months was 0.013 QALYs.
The intervention group was associated with signiﬁcantly higher
quality-of-life weights from the modiﬁed EQ-5D at Month 1, 3, 6 and
12. Speciﬁcally, at Month 1, the weights were 0.06 points (S.E.=0.02;
Pb0.01) higher; at Month 3, 0.08 points (S.E.=0.03; Pb0.05) higher;
at Month 6, 0.08 points (S.E.=0.03; Pb0.05) higher; at Month 12, 0.14
points (S.E.=0.04; Pb0.01) higher. The area under the quality-of-life
weight curve showed a gain of 0.088 QALYs.
3.3. Cost effectiveness
The reference case ICERs were calculated including the automated
monitoring as a startup cost. For patientswith depressionwho completed
the trialwithoutmissing follow-ups, incremental cost perDFDgainedwas
US$19.72 per DFD, and US$18,018 to US$36,035 per QALY gained.
For patients with depression who either completed follow-ups or
whose follow-up scores were imputed, incremental cost per DFD
gained was US$26.95, which corresponds to a cost per QALY gained of
between US$24,774 and US$49,549, when evaluated by the range in
quality-of-life gains found in the literature. For the modiﬁed EQ-5D,
the incremental cost for all patients was US$10,826 per QALY gained.
Cost per QALY gained from the SF-12 was US$73,286.
As a sensitivity analysis, poststart cost-effectiveness ratios were
projected for new patients who might receive the 12-month
intervention after the trial. This assumed similar physician and
nurse care manager costs in providing care for a similar number of
Table 2
INCPAD incremental cost effectiveness ratios
Effectiveness metric a Δ Cost per patient Δ Effectiveness ICER
DFD (Complete follow-ups) 1189.17 (US$) 60.30 (DFD) 19.72 (US$/DFD)
DFD (Complete and imputed follow-ups) 1189.17 (US$) 44.12 (DFD) 26.95 (US$/DFD)
QALY (derived from DFD complete follow-ups) 1189.17 (US$) .066 QALY to .033 QALY 18,017.73 (US$/QALY) to 36,035.45 (US$/QALY)
QALY (derived from DFD complete and imputed follow-ups) 1189.17 (US$) .048 QALY to .024 QALY 24,774.38 (US$/QALY) to 49,548.75 (US$/QALY)
QALY from EQ-5D 952.72 (US$) .088 (QALY) 10,826.48 (US$/QALY)
QALY from SF-12 (SF-6D) 952.72 (US$) .013 (QALY) 73,286.92 (US$/QALY)
a DFD = depression-free days; QALY = quality-adjusted life years.
602 S.J. Choi Yoo et al. / General Hospital Psychiatry 36 (2014) 599–606patients but lower automatedmonitoring costs due to the fact that the
system had already been set up and only maintenance costs would be
required (Table 3). For patients with depression who completed the
trial without missing follow-ups, poststartup incremental cost per
DFD gained was US$13.48, which corresponds to US$12,311 to US
$24,623 per QALY gained.
For patients with depression who either completed follow-ups or
whose responses were imputed, poststartup incremental cost per DFD
gained was US$18.42, which corresponds to US$16,928.13 to US
$33,856.25 per QALY gained.
Post start-up incremental cost per QALY gained was US$7,564 for
all patients using the modiﬁed EQ-5D weights and US$51,199 using
the SF-12 quality-of-life weights.
4. Discussion
Centralized telecare management coupled with automated symp-
tom monitoring for cancer patients with pain and depression
signiﬁcantly increased DFDs and associated QALYs compared to usual
care. Intervention cost of telecare management was greater than usual
care. The range of point estimates for the ICER calculated from various
outcome measures was within the range of other disease management
interventions and generally below US$50,000 per QALY [13–16,27,28].
Effectiveness of the INCPAD intervention may persist beyond
conclusion of the intervention. The Improving Mood: Promoting
Access to Collaborative Treatment trial conducted a 12-month
collaborative care management program for depressed older primary
care patients and found that effectiveness beneﬁts were sustained at
2-year follow-up and the intervention group had lower healthcare
costs during the 4-year follow-up period [29,30]. If the improved
depression outcomes generated by the INCPAD intervention were to
persist beyond the 12-month trial, the ICERs would be even lower.
RegardingDFDs, our study in patientswith cancer compares favorably
to nine previous studies conducted in primary care populations (Table 4).
The latter have shown that a variety of interventions yield annualized
gains inDFDsof 25.2 to58DFDs (compared to60.2DFDs in INCPAD)anda
cost per DFD of US$2.76 to US$35.15 (compared to US$19.72 in INCPAD).
The cost effectiveness of telecare management also compares
favorably with many other cancer treatments. Some new anticancer
drugs have costs per QALY exceeding US$100,000 to US$200,000
[31–33]. Moreover, drivers of increased costs include not only newTable 3
INCPAD postStartup Projected Incremental Cost Effectiveness Ratios for New Patients Recei
Effectiveness Metrica Δ Cost per patient
DFD (complete follow-ups) 812.55 (US$)
DFD (complete and imputed follow-ups) 812.55 (US$)
QALY (derived from DFD complete follow-ups) 812.55 (US$)
QALY (derived from DFD complete and imputed follow-ups) 812.55 (US$)
QALY from EQ-5D 665.59 (US$)
QALY from SF-12 (SF-6D) 665.59 (US$)
⁎ Poststart-up costs are projected to be US$134,450 for 202 new patients receiving the IN
receiving the intervention. This is based upon the assumption that physician and nurse care
months as in the trial, but that only automated symptom monitoring (ASM) costs would b
a DFD = depression-free days; QALY = quality-adjusted life years.drugs but also advances in therapeutic radiology, imaging and other
treatment [34,35]. In contrast, the estimated cost of the INCPAD
intervention ranged from US$7500 to US$75,000 per QALY, with most
CEA methods yielding an estimate under US$50,000.
Thewide range in ICERs produced by different QALYmethodsmay be
due to several factors. Numerous studies have shown that the EQ-5D and
SF-12 (SF-6D) — two of the most commonly used measures in cost-
effectiveness analyses — can produce substantially divergent ICERs [19–
25], depending upon type of disease studied, severity of disease and
fundamental differences between themeasures (score distributions,ﬂoor
and ceiling effects, responsiveness to interventions and other factors).
Second, we used a modiﬁed version of the EQ-5D in INCPAD. Third, the
DFDmethodof calculatingQALYs could only be applied to the subgroupof
depressed patients, although the latter did constitute 76% (309/405) of
our study sample. Because ICERs may vary by type of QALY method, the
calculation of QALYS by several methods provides a type of sensitivity
analysis for estimating the range in which the true ICER is likely situated.
Our cost-effectiveness analysis has three limitations. First, because
the INCPAD trial intervention focused on community-based rural and
urban oncology practices (many of which lacked electronic medical
records and integrated health care systems), our analysis was limited to
intervention costs rather than total health care costs. However, self-
reported health care use as well as co-interventions did not differ
signiﬁcantly between intervention and control groups, and indeed,
there was a trend for lower rates of hospitalization and emergency
department use (two of the more expensive health care use indicators)
in the intervention group [11]. Thus, it is unlikely that health care costs
were higher in the intervention group. Cost-effectiveness acceptability
curves are desirable in CEAs but require patient-level data on both cost
and effectiveness. Likemany trials facing the additional cost of the large
number of additional participants required topower a cost analysis, ours
focused on the effectiveness side and provided patient-level results only
for measures of DFD and QALYs. Thus, there were neither patient-
speciﬁc cost observations nor information on the distribution of total
costs on which to base a bootstrapping analysis. However, costs
included the cost of the intervention alone and not any potential cost
savings from less medical care (e.g., fewer hospital days or emergency
department visits). Thus, the ICERs we have calculated are most likely
conservative, which is desirable when trying to evaluate the cost-
effectiveness of a new intervention. Second, our study found signiﬁcant
improvements in only three of the four measures investigated. Third,ving the Intervention⁎
Δ Effectiveness ICER
60.30 (DFD) 13.48 (US$/DFD)
44.12 (DFD) 18.42 (US$/DFD)
.066 to .033 (QALY) 12,311.36 (US$/QALY) to 24,622.73 (US$/QALY)
.048 to .024 (QALY) 16,622.13 (US$/QALY) to 33,856.25 (US$/QALY)
.088 (QALY) 7,563.52 (US$/QALY)
.013 (QALY) 51,199.23 (US$/QALY)
CPAD intervention and US$125,132 for the subset of 154 new depressed patients
manager times would be the same for treating the same number of new patients for 12
e needed since the ASM system would already be set up.
Table 4
Incremental per patient costs and effectiveness of depression care interventions compared to usual care
Study a Year Intervention Duration
(months)
Costs
captured b
DFDs per patient Incremental
outpatient
costs per patient
(dollars)
QALY methodc
Int Dir Ind In trial Annualized Total Per DFD
Katon et al d [41,42] 1995,1998 Psychiatrist collaborative care 6 ✔ ✔ 15.8 31.6 383 24.24 None
Katon et al d [42,43] 1996,1998 Psychologist collaborative care 6 ✔ ✔ 13.4 26.8 471 35.15 None
Schulberg et al [13,44] 1996,1998 Pharmacotherapy or
Interpersonal psychotherapy
12 ✔ ✔ ✔ 49–58 49–58 - 13.14–17.56 DFD US$11,270–US$19 510
Katzelnick et al [45,46] 2000,2001 Depression care management 12 ✔ ✔ 47.4 47.4 675 14.24 None
Simon et al d [47] 2000 Telephone care management 6 ✔ ✔ 12.6 25.2 130 10.32 None
Simon et al [14] 2001 Stepped collaborative care 6 ✔ ✔ 16.7 33.4 242 14.49 None
Schoenbaum et al [15] 2001 Quality improvement 24 ✔ ✔ 36.5 36.5 - - DFD, SF12 US$9.478–US
$36,467
Katon et al [16] 2005 Collaborative care (late life) 12 ✔ ✔ 52.6 52.6 - 2.76 DFD US$2,519–US$5,037
Rost et al [48] 2005 Depression care management 24 ✔ ✔ ✔ 59.4 29.7 470–
701
7.91–11.80 DFD US$9,592 to US$14,306
Choi-Yoo et al 2014 Telecare management (cancer) 12 ✔ 60.3 60.3 1189 19.72 DFD, SF-12, EQ5D, Global QoL
US$10,829–US$73,287
a All studies except that by Choi-Yoo were conducted in primary care populations. An additional primary care study by Pyne et al. [33] showed no signiﬁcant incremental effect of
the intervention on DFDs.
b Int = intervention costs; Dir = other direct health care costs not related to intervention; Ind = indirect costs.
c If QALYs calculated in article, the method (metric) used to calculate QALYs. SF-12 =Medical Outcome Study 12-item Short-Form. EQ5D= 5-item EuroQoL. Global QoL = single
item overall quality of life.
d Some of DFD data and/or cost per DFD not in original article(s) but in the summary table in Simon et al. 2001 article [14].
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and responses for the EQ-5D from the responses to questions fromother
survey instruments. That this method translated into quality-of-life
weight improvements that were consistent with the improvements
found using two of the other effectiveness measures gave us a level of
conﬁdence in the validity of this measure.
Although INCPAD focused on depression and pain, telephone-based
management has also proven effective for multiple cancer-related
symptoms [36,37]. Cancer symptoms frequently cluster so that many
patients often have more than one type of symptom [10,38,39]. Thus,
providing centralized telecare management for a range of cancer-
related symptoms might further enhance its cost-effectiveness. In
addition, increasing the number of patients who can have their
symptommanagement optimized at homewithout the time and travel
costs of coming to the clinic makes the care more convenient and less
costly from the perspective of the patient. Thiswas reﬂected by the high
patient adherence to and satisfaction with the telecare intervention in
the INCPAD trial [40]. Given the high symptom burden associated with
cancer in all its stages, the responsiveness of symptoms to a cost-
effective telecaremanagement approachmakes this a promising avenue
for improving quality of life in cancer patients.
Appendix 1. Effectiveness metrics
1.A. Converting DFD to QALY
−0.2 to −0.4 QALY = 1 year of depression
X= DFD=365ð Þ year of depression ¼−0:2 to−0:4 QALY=1 year of depression
Solve for X
Where:
Y = incremental DFD/365
60.30/365=0.1652
44.12/365=0.1209
0.1652 * −0.2=−0.0330 QALY
0.1652*−0.4=−0.0661 QALY0.1209 * −0.2=−0.0242 QALY
0.1209 * −0.4=−0.0484 QALY
1.B. ICER = ΔCOST/ΔDFD
DFD
DFD ICER = 1249.68/60.30= 20.72
DFD imputed
DFD imputed ICER = 1249.68/47.25 = 26.45
SF-12
ΔQALY = area between the curves
Area under intervention curve fromMonth 3 toMonth 12—Area
under control curve from month 3 to month 12
ΔQALY = area inside big triangle — area inside small triangle
ΔQALY= (QOL_intervention *0.75year)/2 – (QOL_control*0.75year)/2
(.647 * 0.75)/2 - (.613*0.75)/2 = .013
SF6 ICER = 952.72/.013 = 73286.92
EQ-5D
ΔQALY = area between the curves
ΔQALY=(area under intervention curve fromMonth 0 toMonth
1 – area under control curve from Month 0 to Month 1) + (area
under intervention curve from Month 1 to Month 3 – area under
control curve fromMonth 1 toMonth 3)+ (Area under intervention
curve from Month 3 to Month 6 – Area under control curve from
Month 3 toMonth 6)+ (Area under intervention curve fromMonth
6 toMonth12–Areaunder control curve fromMonth6 toMonth 12)
ΔQALY=(area insidebig trapezoid–area inside small trapezoid)+
(area inside big trapezoid – area inside small trapezoid) + (area
inside big trapezoid – area inside small trapezoid)+ (area inside big
trapezoid – area inside small trapezoid).ΔQALY = [(.404+.49) *(1/12)/2 – (.411+.427)*(1/12)/2] +
[(.49+.534) *(2/12)/2 – (.427+.458)*(2/12)/2] + [(.534+.558) *
(3/12)/2 – (.458+.477)*(3/12)/2] + [(.558+.574) *(6/12)/2 –
(.477+.437)*(6/12)/2] = .088
EQ-5D ICER = 952.72/.088= 10826.48
Intervention component (202 intervention) Costs (US$)
Physician time 43,226
Nurse care manager time 71,224
Automated monitoring start-up/maintenance 78,000
Total 192,450
Aggregate actual study costs — 154 depressed patients.
Intervention component (154 depressed) Costs (US$)
Physician time 43,226
Nurse care manager time 61,906
Automated monitoring start-up/maintenance 78,000
Total 183,132
Aggregate projected poststartup costs — 202 theoretical new intervention patients.*
Intervention component (202 intervention) Costs (US$)
Physician time 43,226
Nurse care manager time 71,224
Automated monitoring maintenance 20,000
Total 134,450
Aggregate projected poststartup costs — 154 theoretical new depressed patients.⁎
Intervention component (154 depressed) Costs (US$)
Physician time 43,226
Nurse care manager time 61,906
Automated monitoring maintenance 20,000
Total 125,132
⁎ Projected poststartup costs would be the costs for all new patients receiving the
intervention after the study. Physician and nurse time is estimated to be the same for
the same number of patients, but automated monitoring costs are only maintenance
since system is already setup.
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EQ-5D mobility
Two SF-12 items used were limitations in moderate activities and in
climbing. “Doesyourhealthnow limit you inmoderateactivities, suchas
moving a table, pushing a vacuum cleaner, bowling, or playing golf; and
in climbing several ﬂights of stairs?” SF-12 response choices were “1.
Yes, limited a lot; 2. Yes, limited a little; 3. No, not limited at all.”
If the moderate activities response was 2 or 3 and the climbing
response was 2 or 3, this was mapped to modiﬁed EQ-5D mobility of:
1. “I have no problems in walking about.”
If moderate activities response was 1 and climbing response was 2
or 3, this was mapped to modiﬁed EQ-5D mobility of: 2. “I have
moderate problems in walking about.”
If moderate activities response was 2 or 3 and climbing response
was 1, then the response was mapped to modiﬁed EQ-5D mobility of:
2. “I have moderate problems in walking about.”
If moderate activities responsewas 1 and climbing responsewas 1,
then the response was mapped to modiﬁed EQ-5D mobility of: 3. “I
am unable to walk about.”
EQ-5D Self-care
The response from survey item (bed days) “During the
past 4 weeks, how many days did your physical health or
emotional problems keep you in bed all or most of the day?
Your answer may range from 0 to 28 days.” was mapped to
EQ-5D self-care response.
If bed days response was 0 to 6 days, this was mapped to modiﬁed
EQ-5D self-care of:
1. “I have no problems washing or dressing myself.”
If bed days response was 7 to 13 days, this was mapped to
modiﬁed EQ-5D self-care of:
2. “I have moderate problems washing or dressing myself.”
If bed days response was 14 to 28 days, this was mapped to
modiﬁed EQ-5D self-care of:
3. “I am unable to wash or dress myself.”
EQ-5D Usual activities
The response from Sheehan Disability Index (SDI) was mapped to
EQ-5D usual activities response. The SDI asks to what extent health
has interfered with the respondent's work, family life and social life
in the past month, each on a scale of 0, not at all to 10, unable to carry
on any activities. Responses were averaged to construct the SDI score.
If SDI score was 0 to 3.49, then the response was mapped to
modiﬁed EQ-5D.
1. “I have no problems doing my usual activities.”
If SDI score was 3.50 to 6.99, then the response was mapped to
modiﬁed EQ-5D.
2. “I have moderate problems doing my usual activities.”
If SDI score was 7.0 to 10, then the response was mapped to
modiﬁed EQ-5D.
3. “I am unable to do my usual activities.”
EQ-5D pain and discomfort
Two BPI items used were average pain in the past week and
current pain, each rated on a 0 to 10 scale where 0 is no pain and 10 is
pain as bad as you could imagine. The responses to these two items
were averaged to construct the BPI score.
If BPI score was 0 to 3.49, then the response was mapped to
modiﬁed EQ-5D.
1. “I have no pain or discomfort.”
If BPI score was 3.50 to 6.49, then the response was mapped to
modiﬁed EQ-5D.2. “I have moderate pain or discomfort.”
If BPI score was 6.50 to 10, then the response was mapped to
modiﬁed EQ-5D.
3. “I have extreme pain or discomfort.”
EQ-5D mood (anxiety and depression)
Responses tooneGeneralizedAnxietyDisorder (GAD-7) scale itemand
four Hopkins Symptom Checklist (SCL-20) depression items were used.
The GAD-7 item used was: “Over the last 2 weeks have you been
bothered by feeling nervous, anxious or on edge?” Responses were: 0
(not at all), 1 (several days), 2 (more than half the days) or 3 (nearly
every day). These were then recoded as 1 (if 0), 2 (if 1 or 2) or 3 (if 3).
The four SCL-20 items used were: “Overall, in the past 4 weeks
how much were you distressed by a) feeling lonely or blue…
b) feeling no interest in things… c) inability to take pleasure in
things… d) feeling hopeless about the future.” Responses for each
item were 0 (not at all), 1 (a little bit), 2 (moderately), 3 (quite a bit) or
4 (extremely). The responses to these four items were averaged to
construct the SCL-20 depression score, which was then recoded as 1
(if 0 to 0.99), 2 (if 1.0 to 2.49) or 3 (if 2.50 to 4.0).
If both the GAD-7 and the SCL-20 were 1, this was mapped to
modiﬁed EQ-5D mood of:
1. “I am not anxious or depressed.”
If either the GAD-7 or the SCL-20 was 3, this was mapped to a
modiﬁed EQ-5D mood of:
3. “I am extremely anxious or depressed.”
All other GAD-7 and SCL-20 combinations were mapped to a
modiﬁed EQ-5D mood of:
2. “I am moderately anxious or depressed.”Appendix 2. Detailed INCPAD cost determination
Aggregate actual study costs — 202 intervention patients
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• Weekly care management conferences: 456 h
• Stafﬁng outside care management conferences: 590+585 min =
1175 min ~ 20 h
• Training nurse manager: 8 h
• Total hours: 484 h
• Physician hourly costs: US$89.31, calculated as follows:
○ US$214,354annuallywith22% fringe,US$175,700without fringe
○ Hours per year: 50 per week × 48 weeks = 2400 h
○ Hourly costs: 214,354/2400 = US$89.31
• Total physician costs: 484 × US$89.31 = US$43226.04
Nurse care manager costs: US$71,224 all patients; [US$61,906
depressed only]
• Total time outside of care manager conference: 1401 h
• Total timeoutsidecaremanager conference(depressedonly):1157h
• Weekly care management conferences: 456 h
• Training time: 8 h
• Total hours: 1865 h
• Total hours (depressed only): 1621 h
• Nurse hourly costs: US$38.19, calculated as follows:
○ US$73,322 annually with 22% fringe, US$60,100 without fringe
○ Hours per year: 40 per week × 48 weeks × 40 = 1920 h
○ Hourly costs: 73,322/1920 = US$38.19
• Total nurse costs (all patients): 1865 × US$38.19 = US$71,224
• Total nurse costs (depressed only): 1621×US$38.19=US$61,906
Automated symptom monitoring costs: US$78,000
• Possibly an overestimate since most of cost (US$50,000) is start-
up, and once in place this could continue to provide care for
thousands of patients at lowmaintenance costs. Thus, a sensitivity
analysis is to estimate poststart-up incremental costs as well.
Calculating weekly care management conference hours: 456 h
• 336 h→ 42 months
○ 30-month enrollment & 12-month follow-up (March 2006
through August 2009)
○ 2 h per week for 12 months (ﬁrst 4 months and last 8 months
of study period) and 3 h per week for 30 months.
○ 48workweeks/12month→ (48weeks × 2 h)+ (120weeks ×
3 h) = 96 h + 360 h = 456 h
Nurse care manager time outside weekly stafﬁng conference
• All 202 intervention patients = 1401 h
○ [Nurse B: 57,946 min/60 = 965.8 h] + [Nurse S: 26,128 min/
60 = 435.5 h]
• 154 depressed patients only = 1157 h
○ [NurseB:47,199min/60=786.7h]+[NurseS:22,211min/60=
370.2 h]
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